MX2020007067A - Composiciones que comprenden nanoparticulas a base de lipidos para el tratamiento de la diabetes mellitus. - Google Patents

Composiciones que comprenden nanoparticulas a base de lipidos para el tratamiento de la diabetes mellitus.

Info

Publication number
MX2020007067A
MX2020007067A MX2020007067A MX2020007067A MX2020007067A MX 2020007067 A MX2020007067 A MX 2020007067A MX 2020007067 A MX2020007067 A MX 2020007067A MX 2020007067 A MX2020007067 A MX 2020007067A MX 2020007067 A MX2020007067 A MX 2020007067A
Authority
MX
Mexico
Prior art keywords
diabetes mellitus
lipid
compositions
treating diabetes
based nanoparticles
Prior art date
Application number
MX2020007067A
Other languages
English (en)
Spanish (es)
Inventor
W Blair Geho
Original Assignee
Sdg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sdg Inc filed Critical Sdg Inc
Publication of MX2020007067A publication Critical patent/MX2020007067A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2020007067A 2018-01-05 2019-01-07 Composiciones que comprenden nanoparticulas a base de lipidos para el tratamiento de la diabetes mellitus. MX2020007067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614109P 2018-01-05 2018-01-05
PCT/US2019/012557 WO2019136386A1 (en) 2018-01-05 2019-01-07 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2020007067A true MX2020007067A (es) 2020-09-09

Family

ID=67143976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007067A MX2020007067A (es) 2018-01-05 2019-01-07 Composiciones que comprenden nanoparticulas a base de lipidos para el tratamiento de la diabetes mellitus.

Country Status (11)

Country Link
US (2) US20200375913A1 (https=)
EP (1) EP3735232A4 (https=)
JP (1) JP7517691B2 (https=)
KR (1) KR20200106912A (https=)
CN (1) CN111712236A (https=)
AU (2) AU2019205795A1 (https=)
BR (1) BR112020013460A2 (https=)
CA (1) CA3086771A1 (https=)
MX (1) MX2020007067A (https=)
SG (1) SG11202005920PA (https=)
WO (1) WO2019136386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
JP7306718B2 (ja) 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
CA3136665A1 (en) 2019-04-12 2020-10-15 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US9872890B2 (en) * 2003-03-19 2018-01-23 Paul C. Davidson Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
EP1610758A4 (en) 2003-03-19 2011-11-02 Harry Hebblewhite METHOD AND SYSTEM FOR DETERMINING INSULIN DOSAGE PLANES AND CARBOHYDRATE / INSULIN RELATIONSHIPS IN DIABETICS
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US20100129428A1 (en) 2005-05-23 2010-05-27 Sdg, Inc. Supra molecular construct for delivery of interferon to a mammal
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) * 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
JP5819949B2 (ja) * 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
CN103501821A (zh) * 2011-03-08 2014-01-08 艾克塞斯制药公司 用于递送活性剂穿过生物膜的靶向纳米载体系统
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子

Also Published As

Publication number Publication date
WO2019136386A1 (en) 2019-07-11
AU2024266969A1 (en) 2024-12-19
CN111712236A (zh) 2020-09-25
JP2021509900A (ja) 2021-04-08
BR112020013460A2 (pt) 2020-12-01
EP3735232A4 (en) 2021-09-08
CA3086771A1 (en) 2019-07-11
US20240108585A1 (en) 2024-04-04
KR20200106912A (ko) 2020-09-15
US20200375913A1 (en) 2020-12-03
EP3735232A1 (en) 2020-11-11
JP7517691B2 (ja) 2024-07-17
SG11202005920PA (en) 2020-07-29
AU2019205795A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MX2017006246A (es) Compuestos de silicona.
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
EP4417164A3 (en) Textured surfaces for breast implants
PH12018501009A1 (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX365458B (es) Agonistas de glucagon/peptido similiar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
MX2020007067A (es) Composiciones que comprenden nanoparticulas a base de lipidos para el tratamiento de la diabetes mellitus.
TN2019000210A1 (en) Antitumoral compounds
MY192040A (en) Elastomer composites, blends and methods for preparing same
ZA202503350B (en) Semaglutide in medical therapy
ZA202507394B (en) Semaglutide in cardiovascular conditions
MY185114A (en) Improved il-6 antibodies
MX366636B (es) Nuevo derivado de un análogo de insulina.
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
ZA202108217B (en) Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
EP3127929A4 (en) Polymerizable composition containing reactive fluorinated silicone compound
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
MX2019010572A (es) Composicion que comprende avelumab.
NZ730759A (en) 1,2-benzothiazole compounds for the treatment of kidney disorders
MX2017000087A (es) Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.
HK40040909A (en) Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
UA95733U (uk) Очні краплі